Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourLeaning Bearish
15 minBearish
5 minDescending Triangle
Daily trend turns up above $9.90
Key levels
Resistance$8.66
Resistance$6.90
Support$6.19
Support$5.78
Latest news & SEC filings
DealEmbecta, Pfizer team up on metabolic health care
EarningsEmbecta posts fiscal Q3 2026 results, updates guidance
SEC FilingEmbecta Corp. filed an insider trading report (Form 4)
All EMBC news →Embecta is a medical device company focused on diabetes care. It makes pen needles, insulin syringes, and safety injection devices used with pen injectors and insulin vials. Its products reach healthcare providers, hospitals, pharmacies, and retail channels in over 100 countries, with manufacturing in Ireland, the United States, and China.
Based on the company's 10-K filed Nov 25, 2025.
Nasdaq · Healthcare
SEPT Low Target
$3.00
SEPT Mid Target
$3.00
SEPT High Target
$3.00
Analyst Consensus
$3.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for EMBC.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/E Forward, PEG, Analyst Consensus
Fair Value
$9.64
25
Moat Score
NONE
6/9
Piotroski Score
N/A
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Morris Milton Mayo | director | Sale | 6,293 | $37K | Sep 4, 2026 |
| Roth Anthony M. | officer | Buy | 30,000 | - | Jun 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-3.8%
3yr Revenue CAGR
-1.5%
EPS Growth YoY
20.9%
FCF Growth YoY
816.6%
Revenue Trend
DECLINING
SEPT Investing tracks real-time dark pool institutional trades for EMBC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:23 | $6.53 | 6,460 | $$42K | BUY |
| 21:00:23 | $6.53 | 1,219 | $$8K | BUY |
| 20:59:06 | $6.50 | 5,887 | $$38K | MIDPOINT |
| 20:58:37 | $6.51 | 1,000 | $$7K | MIDPOINT |
| 20:56:35 | $6.49 | 1,200 | $$8K | SELL |
5 dark pool trades shown · $$103K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Embecta Corp. (EMBC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Embecta Corp. (EMBC) is at $6.53, up 1.56% (+$0.10) at the Nov 11, 2026 close.
Latest EMBC news — Nov 5, 2026: Embecta, Pfizer team up on metabolic health care · Nov 1, 2026: Embecta posts fiscal Q3 2026 results, updates guidance
The average analyst price target for EMBC is $3.00, ranging from $3 to $3, based on 1 analysts. Latest: B of A Securities maintains on May 18, 2026.
Analyst ratings for EMBC: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
EMBC last reported on Aug 7, 2026: EPS $0.56 vs $0.27 expected — a beat of 110.7%.
EMBC trades at a P/E of 4.1 vs a Healthcare average of 17.7.
Yes. EMBC's dividend yield is 4.25%.
Support: $6.19, $5.78, $4.87. Resistance: $6.90, $8.66, $9.43.
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
Nov 5, 2026: Embecta, Pfizer team up on metabolic health care · Nov 1, 2026: Embecta posts fiscal Q3 2026 results, updates guidance · Sep 8, 2026: Embecta Corp. filed an insider trading report (Form 4)